137 results about "Drug content" patented technology

The invention discloses a macloxvir oral soluble film agent and a preparation method thereof, and relates to the technical field of medicines. The macloxvir oral soluble film agent comprises the following components in percentage by weight: 10%-20% of macloxvir, 10%-70% of a film-forming material, 3%-15% of a disintegrating agent, 2%-25% of a plasticizer, 0%-5% of a flavoring agent and 0%-3% of an auxiliary material. The macloxvir oral soluble film preparation has the advantages of no irritant taste, smooth surface, uniform drug content, fast disintegration speed, fast absorption, convenient administration, and improvement of the compliance of patients. The film agent can be used for resisting viruses.

The invention provides a film agent of lumepirone or salt thereof and a preparation method of the film agent, and relates to the technical field of medicines. The lumepirone injection comprises the following raw materials in parts by mass: 2-30 parts of lumepirone or pharmaceutically acceptable salt thereof, 40-95 parts of a film-forming material, 1-30 parts of a plasticizer and 0.1-5 parts of an antioxidant, the antioxidant is selected from at least one of butylated hydroxyanisole, butylated hydroxytoluene and sodium hydrogen sulfite. The film agent is used for drug delivery through oral mucosa or a sublingual way, so that the bioavailability of the drug can be remarkably improved, the blood concentration can be increased, the drug content in the brain and the D2 target spot occupancy rate can be increased, and the curative effect of the film agent can be effectively enhanced.

The invention relates to the field of drug analysis, and discloses a trace analysis method and system for antiviral drugs in sewage based on LC-MS / MS. The method comprises the following steps: filtering a sewage sample, analyzing the drug properties of the antiviral drugs, carrying out solid-phase extraction on the filtered sewage sample, preparing an LC-MS / MS module of the extracted sample, determining a mobile phase of a chromatographic column, and determining the mobile phase of the chromatographic column. Balancing the chromatographic column, constructing chromatographic conditions for balancing the chromatographic column, determining a tuning solution and a mass axis calibration compound of a mass spectrometer, calibrating the mass spectrometer, and constructing mass spectrum conditions of the calibrated mass spectrometer; the method comprises the following steps: preparing a standard solution containing an antiviral drug, analyzing the standard solution, constructing a standard curve of the standard solution, and calculating a response coefficient of an LC-MS / MS module; and analyzing the extracted sample to obtain a sample mass spectrum and a sample chromatogram, and calculating the content of the antiviral drug. According to the method, the sensitivity and accuracy of trace analysis of the antiviral drugs in the sewage can be improved.

The invention provides an airway stent, and relates to the technical field of airway stents. Ozone gas is contained in the storage bottle body, the internal space of the storage bottle body is in a circular ring shape, and a sealing bottle cap is buckled on the top of the storage bottle body; the memory metal support is located in the annular space in the storage bottle body. A rubber sealing ring is installed in the sealing bottle cap, the storage bottle body is sleeved with a movable sleeve shell, and the top of the movable sleeve shell is connected with the sealing bottle cap. A spring is connected into the movable sleeve shell and connected with the storage bottle body. When the memory metal stent is placed in the airway of a patient, the melt degradation film is degraded by body fluid, the inhibition medicine is slowly released from the slow release micropores, and granulation hyperplasia in the airway is inhibited for a long time. The problems that an existing medical airway stent mostly adopts a coating film drug-containing mode for adjuvant therapy, due to the fact that an outer side coating film is thin, the drug content is small, the drug contained in the coating film can be completely released in a short time, and the effect is not long enough are solved.

The invention provides a pramipexole oral soluble film composition as well as a preparation method and application thereof. The invention provides a pramipexole oral soluble film composition. The pramipexole oral soluble film composition comprises an active medicine, a film-forming material, a plasticizer and a flavoring agent, the active drug is a hydrochloride of S-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)-benzothiazole as shown in a formula I and / or other pharmaceutically acceptable salt forms of the hydrochloride of S-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)-benzothiazole as shown in the formula I. The pramipexole oral soluble film composition has the advantages that the pramipexole oral soluble film composition is thin in thickness, fast in disintegration, free of grit feeling after being dissolved in the oral cavity, capable of improving the taste of a medicine and improving the compliance of a patient, capable of being instantly dissolved in the oral cavity without drinking water, fast in oral absorption speed, uniform in film appearance, high in tensile capacity, good in flexibility and long in service life. Meanwhile, the raw materials are easy to obtain, the process is simple, the operation is simple and convenient, the drug loading capacity is high, the drug content uniformity is good, and the preparation method is suitable for industrial production. # imgabs0 #

The invention discloses an anti-idiotypic antibody and application, the provided anti-idiotypic antibody is a monoclonal antibody capable of being specifically combined with a corresponding PD-L1 antibody drug, and the content of the antibody drug in a human body is reflected through the anti-idiotypic antibody; the anti-idiotype antibody disclosed by the invention is prepared by adopting a hybridoma technology, and an ADA kit adopting the antibody can quantitatively detect the concentration level of a PD-L1 antibody drug in vivo, and has a remarkable effect in pharmacokinetic research.

The present application belongs to the technical field of pharmaceutical preparations, and specifically provides a compound SYN045 soft capsule and a preparation method thereof. The present application adopts a fixed proportion of plant oil and polyoxyethylene glyceryl oleate combination to prepare the content, which helps to reduce the degradation of SYN045 in the content drug solution, ensures the stability of the active ingredient, and obtains a compound SYN045 soft capsule with good drug dissolution, high drug content, low impurity generation, and high bioavailability. Further, through prescription optimization of the soft capsule shell, a fixed proportion of plasticizer is selected, the mass ratio of glycerol and sorbitol is 1:2-3, the transfer of the compound SYN045 to the soft capsule shell is reduced, and thus the quality stability problem of the soft capsule preparation product during drug storage is solved.

The invention discloses a pretreatment method and application of a mirabegron resin compound, and relates to the pretreatment method of the mirabegron resin compound, which comprises the following steps: extracting the mirabegron resin compound by an extraction solvent to obtain a sample to be detected for detection; wherein the extraction solvent comprises an aprotic solvent, an ionized solvent and a counter-ion solvent. According to the method, a multi-factor synergistic strategy is adopted, the extraction time of mirabegron in the mirabegron resin compound is remarkably shortened, the medicine extraction efficiency is remarkably improved, the extraction method is high in recovery rate, meanwhile, comprehensive optimization of quality is ensured, a foundation is laid for accurate determination of the medicine content, the consistency of the medicine effect is ensured, and the method is suitable for large-scale popularization and application. The requirements of links such as drug research and development, production and quality control are met.

A method for measuring drug content indexes of a non-viral nucleic acid vector composition, comprising performing labeling by enabling a permeable nucleic acid dye to be in contact with a non-viral nucleic acid vector (for example, an mRNA-LNP). The drug content indexes are calculated by measuring, at a single-particle level, fluorescent light generated by free nucleic acids of a nucleic acid vector, and fluorescent light generated by externally adsorbed nucleic acids and internally entrapped nucleic acids of the non-viral nucleic acid vector. The drug content indexes include a drug loading capacity, entrapment efficiency and the like. The method optionally further comprises: treating a sample with a nuclease before or after performing labeling by using the permeable nucleic acid dye, and when performing treatment with the nuclease, measuring the fluorescence condition of the non-viral nucleic acid vector composition; or enabling the permeable nucleic acid dye to be in contact with the sample, and then measuring the fluorescence condition of the non-viral nucleic acid vector composition.

A magnesium aluminum carbonate double-layer tablet is obtained by pressing a magnesium aluminum carbonate common layer and a magnesium aluminum carbonate sustained-release layer, wherein the magnesium aluminum carbonate common layer contains magnesium aluminum carbonate as a main drug, and the auxiliary materials are a filler and a disintegrant, and the magnesium aluminum carbonate sustained-release layer contains magnesium aluminum carbonate as a main drug, and the auxiliary materials are a drug administration rate regulator, a gastric floating additive, a swelling agent, a foaming agent, and a hydrophilic gel. The magnesium aluminum carbonate double-layer tablet prepared by the present invention has a stable performance within 24 months, and the main drug content of the common layer and the sustained-release layer hardly changes. The common layer of the magnesium aluminum carbonate double-layer tablet can be completely peeled off from the sustained-release layer in about 30 seconds and sink into the lower layer, quickly neutralizing gastric acid and taking effect quickly. At the same time, the sustained-release layer has a release time of up to 4 hours after forming a floating layer, which proves that the magnesium aluminum carbonate double-layer tablet has a sustained-release effect within 4 hours after administration, and can effectively prolong the treatment time of patients with gastric ulcer and duodenal ulcer.

The present invention relates to a pharmaceutical composition which does not undergo rapid initial burst release of a drug by comprising sustained release microspheres consisting of texipatide or a pharmaceutically acceptable salt thereof, an initial burst release inhibitor, and a biodegradable polymer, has a high drug content with respect to particle size, and has high bioavailability, thus, the composition can minimize patient pain and inflammatory response that may occur when administered to a human body, and thus can be effectively used in the prevention or treatment of diabetes, beta cell dysfunction, hypertension, hyperlipidemia, obesity, and non-alcoholic steatohepatitis.

The utility model relates to the technical field of anthelmintics, and discloses a feed anthelmintics blending and mixing device which comprises a mixing barrel, a feeding pipe and a discharging pipe are arranged on one side of the upper end of the mixing barrel and the middle of the lower end of the mixing barrel respectively, a barrel cover is detachably arranged at the upper end of the mixing barrel, a pesticide feeding pipe is arranged above the barrel cover, and a stirring shaft is rotatably connected to the middle of the lower portion of the barrel cover. The stirring shaft is driven by a motor fixedly arranged above the barrel cover, a spiral stirring blade is fixedly arranged on the stirring shaft, a square stirring frame is arranged on the stirring shaft and located on the outer side of the spiral stirring blade, a plurality of stirring blocks are arranged on two side plates of the square stirring frame, and a plurality of barrier strips are arranged on the inner wall of the mixing barrel. The stirring device has the advantages that the stirring effect on feed and anthelmintic is good, the uniformity is high, and the situation that the local drug content is too high is prevented.

The invention provides a tamsulosin hydrochloride sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: spraying an ethanol water solution of tamsulosin hydrochloride on a mesoporous silica carrier, and drying to obtain a drug-containing carrier; mixing the drug-containing carrier, an auxiliary carrier, an adhesive and water, and carrying out wet granulation to obtain a drug-containing soft material; extruding and rounding the medicine-containing soft material to obtain a medicine-containing pellet core; coating the drug-containing pellet core with a coating solution to obtain a coated pellet core; the coating liquid comprises an enteric-coated material and a plasticizer; and mixing the coated pellet core with a lubricant to obtain the tamsulosin hydrochloride sustained release preparation. The tamsulosin hydrochloride sustained-release preparation prepared by the method is good in drug content stability, stable in main drug release, simple in process, high in controllability and suitable for industrial production.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The invention provides a medicine content detection method combining a respiration simulation device and HPLC (High Performance Liquid Chromatography), which relates to the technical field of medicine detection and comprises the following steps: establishing a mathematical expression of a target medicine net peak area and a target medicine concentration under each respiration parameter combination and a mapping relation between the respiration parameter combination and a target medicine reference peak area; therefore, the target drug net peak area of the to-be-detected gas is determined, a plurality of similar breathing parameter combinations similar to the breathing state under the current breathing parameter combination are screened out, and the accurate value of the target drug concentration of the to-be-detected gas is determined by combining the corresponding confidence coefficient, so that the accuracy of the detection result is ensured, and the detection efficiency is improved. A mathematical expression for solving the target drug concentration under the current breathing parameter combination is established without multiple calibration tests, so that the workload is greatly reduced, and the drug concentration detection efficiency is improved.

The application discloses a multi-module cooperative medicine content uniformity detection pretreatment system and method, and belongs to the technical field of medicine detection. The system comprises a container processing module, a fluid processing module, a constant volume module, a mixing module, a transfer module and a control system. The container processing module realizes automatic cap pulling and cap pressing of non-standard capacity bottles; the fluid processing module realizes liquid injection and pipetting; the constant volume module realizes automatic constant volume through visual identification; the mixing module realizes automatic liquid mixing; the transfer module automatically transfers containers between modules; the control system determines the operation sequence, controls the transfer module to sequentially transfer the containers and triggers each module to perform operations, and simultaneously receives state feedback. Through multi-module cooperative linkage, the application realizes full-process automation of plaster medicine detection pretreatment without manual intervention, significantly improves processing efficiency, precision and consistency, and has state monitoring and data tracing functions.

The invention relates to a suture thread material comprising at least one polymer and at least one eutectic mixture. The polymer can be a biocompatible polymer such as polycaprolactone or PLGA. The eutectic mixture comprises triclosan. Other eutectic mixtures can be used in suture thread materials to reduce SSis and / or to decrease pain and / or to increase lubricity of sutures. The invention also provides a method for the production of sutures with drug loadings, the method comprising the use of therapeutic deep eutectic solvent (THEDES) technology to significantly increase drug content in suture matrices.

The utility model discloses an agricultural product drug residue detection device based on Raman spectrum, and relates to the field of detection devices. The device comprises a full-spectrum pesticide residue detector main body, a detection bin arranged on the top end face of the full-spectrum pesticide residue detector main body, a detection groove formed in the detection bin and used for supporting a detection tube, and a bin cover rotationally connected with a bin opening of the detection bin. According to the agricultural product pesticide residue detection device based on the Raman spectrum, the feeding mechanism is arranged on the top end surface of the bin cover, so that an agricultural product detection sample can be directly added into a detection tube under the condition that the detection tube containing the agricultural product detection sample is not taken out; the pesticide content in agricultural product detection samples of different quantities can be conveniently detected, the feeding mechanism can meet the stable feeding requirements of detection tubes of different sizes through the arranged positioning mechanism, and the practicability is good.

The invention provides Qingkailing dropping pills and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine extraction and preparations, the Qingkailing dropping pills comprise the following raw materials: cholic acid, nacre mother of pearl, hyodeoxycholic acid, cape jasmine, cornu bubali, isatis root, baicalin and honeysuckle; the preparation method comprises the following steps: providing pill paste powder, wherein the pill paste powder is prepared by sequentially drying mixed thick paste under reduced pressure and crushing; the mixed thick paste comprises the following raw materials: a honeysuckle extract, an isatis root-cape jasmine extract, a buffalo horn-nacre mother-of-pearl extract and a cholic acid-baicalin concentrated solution; providing a matrix, and melting and mixing the matrix with the pill paste powder to prepare a molten liquid; and providing a condensing agent, dropwise adding the molten liquid into the condensing agent, and carrying out shrinkage molding, so as to obtain the finished product dropping pill, namely the Qingkailing dropping pill. According to the preparation method, the melting and mixing efficiency and effect of the pill paste powder and the matrix are improved, the texture of molten liquid is more uniform, the content distribution of all effective components is more uniform, the medicine content uniformity in the finished dropping pill is improved, and the obtained finished dropping pill is high in stability, round in appearance and good in uniformity.

The invention discloses an automatic granulation process of a boiling granulation dryer. The automatic granulation process comprises the following steps: S1, building a granulation system; s2, when a fluidized bed is preheated to the feeding temperature, powder is fed into the fluidized bed, and then the powder is heated to the set material temperature; s3, starting automatic segmented granulation; s4, the materials are dried for t5 minutes in a delayed mode; s5, starting material coloring; s6, drying the materials for t7 minutes; and S7, the air inlet temperature is reduced, dry cold air is conveyed into the fluidized bed, the material temperature is reduced, and when the material temperature is smaller than or equal to the discharging temperature value, shutdown is conducted, and the materials are output. According to the invention, the traceability and reducibility of batch products are ensured, and the defects of manual operation are overcome; in the granulating process, the material bed collapse is avoided, and the fullness and uniformity of the medicine component of each granule are ensured.

The invention provides a GK001 solid preparation as well as a preparation method and application thereof. The solid preparation comprises the following components: a GK001 amorphous solid dispersion, an excipient, a diluent, a disintegrating agent and a lubricant, the GK001 has a structure as shown in a formula I which is described in the specification. According to the invention, GK001 is creatively prepared into a solid preparation in the form of amorphous solid dispersion, and the solid preparation has excellent stability and fluidity and high oral availability. The preparation is moderate in hardness and stable in quality, the process requirements are met, and the friability and disintegration time limit both meet the requirements; the dissolution rate of the preparation is basically consistent with the drug content, the plasma exposure is high, and the oral dose of the drug and the plasma exposure are in a linear relationship.

The invention belongs to the technical field of chemical analysis, and discloses an analysis method for determining the content of a main drug of a lansoprazole sodium bicarbonate capsule, and the main scheme is as follows: a methanol-water-triethylamine mixed solution is taken as a diluent, and after dissolution, an ultraviolet spectrophotometry (UV) is directly adopted for determination at the wavelength of 264 nm by an external standard method. According to experiments, methanol and water in the diluent can effectively dissolve the substance, triethylamine as alkali can effectively protect degradation of lansoprazole in the dissolving process, and compared with a determination method for the content of the product in the 2020 edition of Chinese Pharmacopoeia, the determination analysis method has the advantages of high efficiency, convenience, economy and the like.

The invention discloses a preparation method of inositol nicotinate tablets, and belongs to the technical field of pharmaceutical preparations. By optimizing the existing process and coating components, stable dissolution of drugs is realized, and the method comprises the following steps: dispersing inositol nicotinate in mixed oil to prepare an oil phase, mixing and emulsifying the oil phase and a water phase, performing spray drying to obtain drug milk powder, coating the drug milk powder with modified chitosan, and directly tabletting the coated drug milk powder and auxiliary materials. The preparation method comprises the following steps: uniformly dispersing inositol nicotinate in mixed oil to promote the inositol nicotinate to maintain the uniformity of the drug content in the subsequent process, and adsorbing solid particles on the surfaces of drug-containing oil drops through an emulsification technology to protect the drug components; coating components are reasonably designed, so that fixed-point release of the medicine is realized, the medicine is endowed with anti-pressure ability, and the medicine can be directly tableted; and the coated medicine particles are mixed with auxiliary materials and then are directly tableted, so that the process is simplified, and the coating structure of the medicine particles is protected at the same time. The preparation method can prepare the inositol nicotinate tablet with stable drug dissolution, and the inositol nicotinate tablet is good in taste and small in stimulation to gastric mucosa.

The invention relates to the technical field of progesterone sustained-release nanoparticle production, in particular to a progesterone sustained-release nanoparticle which comprises progesterone and further comprises solid lipid and liquid lipid according to the formula ratio of 1: 1.4: 1.2: 0.8. A preparation method of the progesterone sustained-release nanoparticle comprises raw material preparation of progesterone, solid lipid and liquid lipid and melt emulsification. The prepared progesterone lipid nanoparticles have high drug entrapment efficiency which can reach 77.48% at most, and have obvious drug sustained and controlled release performance, although the particle size of the nanoparticles is increased along with the increase of the content of liquid lipid-oleic acid in the lipid nanoparticles, the drug entrapment efficiency is improved, the in-vitro release of the drug is accelerated, and the progesterone lipid nanoparticles have good application prospects. According to the progesterone nanostructure lipid carrier, the drug content in the preparation process of the nanoparticles is improved, the drug encapsulation efficiency of the prepared progesterone nanostructure lipid carrier is reduced, but the drug loading capacity of the nanoparticles can be improved, and when the dosage reaches 20%, the drug loading capacity of the nanoparticles can reach 11.57%.

The invention discloses a combined package of an estradiol tablet and an estradiol didrogesterone tablet and a preparation method of the combined package. The package is composed of an estradiol tablet and an estradiol didrogesterone tablet. The combined package of the estradiol tablets and the estradiol digestrol tablets comprises the estradiol tablets and the estradiol digestrol tablets which are equal in tablet number, each of the estradiol tablets and the estradiol digestrol tablets comprises a tablet core and a coating layer, the tablet cores are prepared by a high-speed shearing granulation and tabletting process, and the prepared tablets are consistent with an originally developed agent Femoston in in-vitro release behavior, and have the advantages that the estradiol tablets and the estradiol digestrol tablets are combined, so that the estradiol and the estradiol digestrol tablets can be used for preparing the estradiol digestrol tablets; and in-vivo bioequivalence can be achieved. The high-speed shearing granulation mode is used for improving the particle mixing uniformity, so that the medicine content is more uniform, the in-vitro dissolution is stable, and the inter-batch difference is reduced. According to the invention, estradiol with a particle size of less than 20 [mu] m and didrogesterone with a particle size of less than 30 [mu] m are selected, high-speed shearing granulation is carried out by using a high stirring frequency, a special water adding device with a specific opening angle is selected, and the water adding amount, the water adding time and the stirring frequency are controlled at the same time, so that the tablets with rapid dissolution, uniform content and stable quality can be obtained.

The invention relates to an inhalation dry powder preparation containing a salmeterol and tiotropium salt composition and a preparation method of the inhalation dry powder preparation, and belongs to the technical field of pharmaceutical preparations. The preparation comprises a long-acting beta-2 adrenergic receptor agonist (LABA) salmeterol and a long-acting anticholinergic drug (LAMA) tiotropium salt, and the efficient synergistic effect of the two drugs is achieved by optimizing a drug micronization process, a carrier particle design, a carrier material and a preparation process. The medicine can penetrate into a lung target region, so that precise treatment is realized. A powder mist inhalation device CN219423486U disclosed by Nanchang large pharmaceutical industry limited company is adopted as a delivery device, and the lung deposition rate and delivery efficiency of the medicine are remarkably improved by controlling the particle size of the medicine, the particle property of a carrier and the uniformity of the preparation. In addition, the invention further provides a preparation method of the preparation, the preparation method comprises the processes of medicine micronization, mixing homogenization and packaging, and the stability and dosage accuracy of the preparation are ensured. Experiments show that in an accelerated stability investigation period as long as 6 months, the drug content, impurity level and fine particle fraction in the preparation are kept stable and do not change significantly, and it is proved that the preparation has good physical and chemical stability and storage performance. The preparation has quick-acting and long-acting bronchiectasia effects, is suitable for long-term management of moderate and severe asthma and chronic obstructive pulmonary disease (COPD), and can significantly improve the medication convenience and treatment compliance of patients.

The invention relates to the technical field of particle raw material stirring and mixing, in particular to a compound dibazol hydrochlorothiazide capsule raw material pretreatment stirring and mixing device which comprises a plurality of treatment frames which are evenly distributed from top to bottom and provided with upward openings, discharging openings are formed in the bottoms of the treatment frames, and stirring mechanisms are installed in the treatment frames; the device adopts a manner of matching layered laying and alternate stacking, active ingredients are independently stirred and flattened, then the active ingredients and auxiliary materials are stacked layer by layer, the active ingredients are uniformly attached to the surfaces of the auxiliary materials through throwing, and multi-stage gradual dilution is carried out, so that the problem that the active ingredients are easy to disperse and non-uniform when being directly mixed can be solved, the medicine content accuracy is improved, and the medicine quality is improved. And the components of each capsule are uniform and reach the standard.

The invention discloses timolol maleate gel emplastrum and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The gel paste comprises timolol maleate, a gel skeleton, a cross-linking agent, a cross-linking regulator, a filler, a penetration enhancer, a tackifier, a humectant, a pH regulator, a preservative and purified water. The preparation method comprises the following steps: preparing an oil phase; preparing the medicine and the water-soluble auxiliary materials into a solution; the tackifier adopts methyl acrylate / acrylic acid 2-ethylhexyl copolymer resin emulsion as a single phase; mixing the oil phase with the solution and the tackifier to obtain uniform gel paste with better ductility; and uniformly coating the paste on a backing layer, covering with a protective layer, and packaging to obtain the timolol maleate gel emplastrum. Through optimized prescription composition and process, the preparation has the characteristics of stable drug content and good skin adhesion, can realize continuous transdermal release of drugs, and is especially suitable for long-term safe treatment of infantile hemangioma.

The present invention discloses a method and device for predicting changes in the content of a drug in a living body. The present invention uses microsomes to construct a kinetic reaction system of a test substance in vitro, allowing the test substance to fully react in the microsomes, and determining the reaction conditions for conducting in vitro kinetic experiments using microsomes. Through the constructed microsomal reaction system, the metabolic rate of the test substance in the liver and / or small intestine of the living body is calculated, and its metabolic kinetic parameters are written into calculus equations using a computer, and then solved to finally obtain the kinetic process of the test substance, thereby making up for the shortcomings of conducting toxicity experiments using in vitro biological tissues. The present invention can analyze the toxicity characteristics of drugs in the liver of mice and predict the dose that produces liver toxicity without the need for animal experiments.